The uptake of F-fluorothymidine (F-FLT) depends on cells' proliferative rates. We compared the characteristics of F-FLT positron emission tomography/computed tomography (PET/CT) with those of F-fluorodeoxyglucose (F-FDG) PET/CT for breast cancer. We prospectively diagnosed patients with breast cancer who underwent F-FLT PET/CT and F-FDG PET/CT. Subsequently, significant differences and correlation coefficients of the maximum standardized uptake value (SUVmax) in primary breast cancer and axillary lymph nodes were statistically evaluated. We enrolled eight patients with breast cancer. In six treatment-naive patients, the SUVmax for primary lesions showed a significant difference (mean, 2.1 vs. 4.1, = 0.031) and a strong correlation ( = 0.969) between F-FLT and F-FDG. Further, although the SUVmax for the axillary lymph nodes did not show a significant difference between F-FLT and F-FDG (P = 0.246), there was a strong correlation between the two (r = 0.999). In a patient-by-patient study, there were cases in which only F-FDG uptake was observed in lymph nodes and normal breasts. Bone metastases demonstrated lower accumulation than bone marrow on the F-FLT PET/CT. In conclusion, a strong correlation was observed between the F-FLT PET/CT and F-FDG PET/CT uptake. Differences in the biochemical characteristics of F-FLT and F-FDG were reflected in the accumulation differences for breast cancer, metastatic lesions, and normal organs.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9611609PMC
http://dx.doi.org/10.3390/tomography8050211DOI Listing

Publication Analysis

Top Keywords

breast cancer
24
positron emission
12
emission tomography/computed
12
tomography/computed tomography
12
patients breast
12
f-fdg pet/ct
12
f-flt pet/ct
12
lymph nodes
12
strong correlation
12
f-flt f-fdg
12

Similar Publications

Background: Over the past twenty years, the post-cancer rehabilitation has been developed, usually in a hospital setting. Although this allows better care organization and improved security, it is perceived as stressful and restrictive by the "cancer survivor". Therefore, the transfer of benefits to everyday life is more difficult, or even uncertain.

View Article and Find Full Text PDF

Triaging mammography with artificial intelligence: an implementation study.

Breast Cancer Res Treat

January 2025

Google Health, 1600 Amphitheatre Pkwy, Mountain View, CA, 94043, USA.

Purpose: Many breast centers are unable to provide immediate results at the time of screening mammography which results in delayed patient care. Implementing artificial intelligence (AI) could identify patients who may have breast cancer and accelerate the time to diagnostic imaging and biopsy diagnosis.

Methods: In this prospective randomized, unblinded, controlled implementation study we enrolled 1000 screening participants between March 2021 and May 2022.

View Article and Find Full Text PDF

Background: The identification of circulating potential biomarkers may help earlier diagnosis of breast cancer, which is critical for effective treatment and better disease outcomes. We aimed to study the role of circ-FAF1 as a diagnostic biomarker in female breast cancer using peripheral blood samples of these patients, and to investigate the relation between circ-FAF1 and different clinicopathological features of the included patients.

Methods And Results: This case-control study enrolled 60 female breast cancer patients and 60 age-matched healthy control subjects.

View Article and Find Full Text PDF

Type 2 diabetes mellitus (T2DM) adversely affects various organs, including the brain and its blood barrier. In addition to the brain, hyperglycemia damages the testes. The testes possess blood-tissue barriers that share common characteristics and proteins with the blood-brain barrier (BBB), including breast cancer-resistant protein (BCRP).

View Article and Find Full Text PDF

Ongoing Symptoms and Concerns Experienced by Low-Risk Breast Cancer Survivors Following Active Treatment.

Ann Surg Oncol

January 2025

Department of Surgery, School of Medicine and Public Health, Wisconsin Surgical Outcomes Research Program, University of Wisconsin, Madison, WI, USA.

Introduction: Little is known about the symptom burden of breast cancer survivors with early-stage disease. Many studies have focused on symptoms of patients who are undergoing or recently completed systemic therapy. However, with the increased use of Oncotype DX, the proportion of early-stage hormone receptor-positive patients who undergo chemotherapy has declined, making existing studies of the symptom experience less useful for these patients.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!